National class action approved for users of this antipsychotic drug
The companies behind a prescription drug that was recently approved to treat symptoms of agitation in Alzheimer’s patients are facing a class-action lawsuit over alleged “harmful side effects” to patients. The lawsuit relates to the antipsychotic drug Rexulti, which was approved by Health Canada in January for managing agitation associated with dementia due to Alzheimer’s … Read more
